Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaxoSmithKline Pakistan has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
GlaxoSmithKline Pakistan's Interest Coverage for the quarter that ended in Jun. 2026 was 519.54.
GlaxoSmithKline Pakistan's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.01.
As of today, GlaxoSmithKline Pakistan's Altman Z-Score is 6.98.
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
GlaxoSmithKline Pakistan has the Financial Strength Rank of 7.
GlaxoSmithKline Pakistan Financial Strength Related Terms
KAR:GLAXO vs ZTS, UTHR: Financial Strength Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Financial Strength vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Financial Strength distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. GlaxoSmithKline Pakistan Ltd has enough cash to cover all of its debt. Its financial situation is stable.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
GlaxoSmithKline Pakistan has a Z-score of 6.98, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 6.98 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Financial Strength of 7 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 30% below median its historical median of 10.00. Over the past decade, GlaxoSmithKline Pakistan's Financial Strength has ranged from 2.00 to 10.00.
Is GlaxoSmithKline Pakistan's Financial Strength too high?
GlaxoSmithKline Pakistan's current Financial Strength of 7 is 30% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Financial Strength compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Financial Strength of 7 can be compared against companies in the Drug Manufacturers industry. Historically, GlaxoSmithKline Pakistan's own Financial Strength has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Drug Manufacturers company?
A good Financial Strength depends on the Drug Manufacturers industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Financial Strength is 7, which is 30% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₨349.30, compared to a current price of ₨325.69 — trading 6.8% below its estimated fair value. The current Financial Strength is 7, which is 30% below median its 10-year median of 10.00. GlaxoSmithKline Pakistan's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Financial Strength is 7 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be undervalued.
The current stock price of ₨325.69 is trading 6.8% below its estimated GF Value™ of ₨349.30.
GuruFocus considers GlaxoSmithKline Pakistan to be Fairly Valued.
Key valuation signals for KAR:GLAXO:
Financial Strength: 7 (30% below median its 10-year median of 10.00)
GF Value™: ₨349.30 vs. price of ₨325.69 (6.8% below fair value)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
94GF Score
Get the complete analysis for KAR:GLAXO
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
